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Research into ageing and its underlying molecular basis enables us to 51	  
develop and implement targeted interventions to ameliorate or cure its 52	  
consequences. However, the efficacy of interventions often differs widely 53	  
between individuals, suggesting that populations should be stratified or even 54	  
individualized. Large-scale cohort studies in humans, similar systematic 55	  
studies in model organisms, and detailed investigations into the biology of 56	  
ageing can provide individual validated biomarkers and mechanisms, leading 57	  
to recommendations for targeted interventions. Human cohort studies are 58	  
already ongoing, and can be supplemented by in silico simulations. 59	  
Systematic studies in animal models are made possible by the use of inbred 60	  
strains, or genetic reference populations of mice. Combining both, the 61	  
comprehensive picture of the various determinants of ageing and healthspan 62	  
can be studied in detail, and an appreciation of the relevance of results from 63	  
model organisms to humans emerges. The interactions between genotype 64	  
and environment, particularly the psychosocial environment, are poorly 65	  
studied in both humans and model organisms, presenting serious challenges 66	  
to any approach to a personalized medicine of ageing. To increase success of 67	  
preventive interventions, we argue that there is a pressing need for an 68	  
individualized evaluation of interventions such as physical exercise, nutrition, 69	  
nutraceuticals and calorie restriction mimetics as well as psychosocial and 70	  
environmental factors, separately and in combination. The expected extension 71	  
of healthspan enables us to refocus healthcare spending on individual 72	  
prevention starting in late adulthood, and on the brief period of morbidity at 73	  
very old age.  74	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Introduction 75	  
 76	  
The need for ageing research is growing rapidly. Trends predicted from the 77	  
EUROPOP survey suggest that the share of the population aged 65 years and over 78	  
will rise from 17% in 2010 to 30% in 2060, with those aged over 80 increasing from 79	  
5% to 12% over the same period   [http://futurage.group.shef.ac.uk/road-map.html]. 80	  
The economic and social consequences of the ageing population therefore cannot be 81	  
overestimated. Slowing down the deleterious processes of ageing itself would enable 82	  
significant benefits, going beyond the benefits of eradicating specific diseases, which 83	  
amount to lifespan extension by just a few years in case of, e.g., cancer and stroke 84	  
[1]. The diseases of age, whether cardiovascular, neoplastic, pulmonary or cognitive, 85	  
are increasing in frequency and will be the top four causes of death worldwide by 86	  
2020. 75% of all deaths from these diseases occur in people aged 60 and over and 87	  
their incidence rises with age. In other words, for a host of non-communicable 88	  
diseases, there is a clear link between the underlying processes of ageing and the 89	  
age-dependent accumulation of risk, so that eradication of one disease merely 90	  
makes way for the occurrence of another disease slightly later [2], [3], [4]. Slowing 91	  
down ageing itself, and addressing its root mechanisms, is expected to increase 92	  
healthspan and to compress the period of age-related morbidity, thus tackling goals 93	  
considered much more worthwhile than simply extending chronological lifespan [3], 94	  
[4]. Moreover, for any interventions, the effect of genotype and environment 95	  
(biological and psychosocial), and of the interaction between underlying mechanisms 96	  
are most important, and their combinatorial application should be considered (Figure 97	  
1).  98	  
 99	  
Therefore, based on the recent convergence of personalized medicine and ageing 100	  
research in human and model organisms, we suggest in this Viewpoint that a 101	  
successful research agenda for the next decade should be based on three pillars 102	  
(Figure 2): (1) extending, complementing and integrating the knowledgebase 103	  
assembled in existing human cohort studies, (2) running closely similar studies in 104	  
animal models, and (3) understanding the biology of ageing through detailed 105	  
investigation of findings in human and animals, to gain a mechanistic understanding 106	  
of biomarkers and interventions.  107	  
 108	  
Our agenda rests on the biomarker concept. Baker and Sprott  [5] defined a 109	  
biomarker of ageing as ‘a biological parameter of an organism that either alone or in 110	  
some multivariate composite will, in the absence of disease, better predict functional 111	  
capability at some late age, than will chronological age’, and the American 112	  
Federation for Aging Research has proposed more detailed criteria for biomarkers of 113	  
ageing aimed at estimating biological, not chronological age [6], essentially adding 114	  
their close relation to processes that underlie ageing, not disease, their ease of 115	  
measurement and their cross-species relevance. However, while many biomarkers of 116	  
ageing were described in animal or cross-sectional human studies, most of them 117	  
failed in the few long-term human studies available [7]. One problem is technical 118	  
limitation: human marker measurements are rarely comparable across decades. 119	  
Also, selecting blood as the most easily assayable biological fluid ignores other 120	  
organs affected by age. Moreover, there are major variations during the day or the 121	  
year, as e.g. the amount of daylight will have an impact on many markers. Also, 122	  
some markers such as low body mass index or blood pressure may indicate lesser 123	  
biological age for younger people only, and the opposite for the very old [9], [10]. 124	  
Finally, while biomarkers should describe biological age, there is no true "gold 125	  
standard", which would need to be based on a comprehensive longitudinal study in 126	  
humans running for almost a century. Studies of populations at an advanced age, 127	  
such as the Leiden or Newcastle 85-plus studies [11], [12], necessarily focus more 128	  
on old-age multimorbidity than on the full spectrum of ageing processes over a 129	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human lifecourse. Nevertheless, listings of biomarkers validated for humans in 130	  
longitudinal studies were compiled and include interleukin 6 (IL-6) and some 131	  
hormones [7], [8], and, more recently, galactosylated N-glycans [13], plasma N-132	  
terminal pro-B-type natriuretic peptide (NT-proBNP) [14] and epigenetic markers [15], 133	  
[16]. 134	  
 135	  
‘Personalized’ approaches to medicine are gaining ground in mainstream medical 136	  
research. The most well-known of these involve cancer therapeutic agents with a 137	  
companion diagnostic gene test, such as HerceptinTM and GleevecTM [17]. More 138	  
comprehensive, ‘omics’-based attempts at personalizing diagnostics and therapy are 139	  
being tested [18]. Moreover, molecular markers and interventions have to be 140	  
integrated with biographical ones [19]. Assembling sufficiently large human datasets, 141	  
in order to enable differentiation and classification of patients within the cohorts, is 142	  
the key to personalized medicine. Longitudinal cohort studies, such as the 143	  
Framingham [20], and Study of Health in Pommerania (SHIP) [21] studies, or the 144	  
upcoming German National Cohort  [22], therefore attempt to identify disease 145	  
mechanisms, risk factors, prevention strategies and early markers in the general 146	  
population; systematic integration of such data is also being attempted 147	  
[http://www.chancesfp7.eu/]. 148	  
 149	  
While the mechanisms of ageing are complex [4], [23], [24], evidence is 150	  
accumulating that ageing is a potentially modifiable risk factor [25] for its associated 151	  
morbidities. Moreover, longitudinal cohort studies for humans (see above) and 152	  
primates [26], [27], human genome-wide association studies [28], as well as 153	  
longitudinal studies, genetic manipulation and intervention testing programs for 154	  
rodents [29], [30], [31] have revealed many insights in recent years. Some of them 155	  
converge on exercise and diet, and associated pathways. In particular, a recurring 156	  
theme is that of pathways related to energy and nutrient sensing and production [32] 157	  
and dietary restriction has emerged as the most robust means of extending lifespan 158	  
and healthspan alike [26]. Dietary restriction may be the best path towards this goal, 159	  
even though its long-term effects in humans are ultimately unknown. Pragmatically, 160	  
its downside is that it requires behavioral modification and great willpower, triggering 161	  
the search for calorie-restriction mimetics, small molecules that produce comparable 162	  
effects, with some promising early results [33]. Importantly, the effects of dietary 163	  
restriction are not uniform: in the case of mice and primates, dietary restriction results 164	  
vary by genotype (or strain or subspecies), diet and/or environment, and dietary 165	  
restriction was sometimes found detrimental [34], just as the effects of its mimetics 166	  
vary [35]. The effects of dietary components vary as well, e.g. whole-grain bread 167	  
tends to have positive effects mostly in Northern European populations and less in 168	  
Mediterranean people [36]. Similarly, the effects of fish oil in mouse and human 169	  
depends on APOE genotype [37]. Thus, we may expect to find a high degree of 170	  
heterogeneity in the informativity of biomarkers, or the efficacy of interventions, for 171	  
humans and in outbred animals alike. Moreover, studies of the underlying molecular 172	  
mechanisms in terms of pathways may also wish to take into account individual 173	  
variability. 174	  
 175	  
Personalized medicine and ageing research are now starting to come together, 176	  
aided by the explorative and confirmatory power of high-throughput datasets. 177	  
 178	  
The most visible sign of this convergence is the recent startup of Human Longevity 179	  
Inc [http://www.humanlongevity.com/] by Craig Venter, aiming at finding genomic, 180	  
metabolomic, microbiomic and other determinants of health in 100,000s of 181	  
volunteers. Along similar lines, the Institute for Systems Biology in Seattle is now 182	  
pursuing the 100k project [http://research.systemsbiology.net/100k/]. As time goes 183	  
by, longitudinal cohort studies are by necessity developing into studies of ageing, 184	  
	   5	  
and a few are explicitly gathering data with the aim of fostering a better 185	  
understanding of ageing processes [38], [39]. Longitudinal studies in model 186	  
organisms enable the systematic dissection of the molecular architecture of ageing. 187	  
For example, around 30 strains of mice have recently been studied by the Nathan 188	  
Shock Center at the Jackson laboratory [29], and phenotypic and/or genetic data are 189	  
now being analyzed together with lifespan data [40], [9], [41]. Efforts such as the 190	  
Collaborative Cross [42] enable Genome Wide Association Study (GWAS)-like 191	  
studies in mice, and the subsequent detailed study of mechanistic insights, and more 192	  
generally the modeling of approaches to personalized medicine in animals. Here, we 193	  
can investigate the individual differences in the biology of ageing seen on the cell, 194	  
tissue and organ level, in great detail. On each of these levels, the speed of ageing 195	  
can vary substantially, and this is reflected, e.g., epigenetically [15], [16]. More 196	  
generally, as described in the introduction, biomarkers of ageing are usually found by 197	  
investigating subpopulations (such as people aged 85 years and older), and these 198	  
biomarkers also allow the stratification of large populations according to the biology 199	  
of ageing. 200	  
 201	  
Whilst association studies may provide information on personal risks for specific 202	  
morbidities, their severity and timing, many of these risks are turning out to be 203	  
modified by the psychosocial environment and individual history, which in 204	  
themselves need to be included not only as part of the risk analysis but also as a 205	  
guide to potential therapies [43]. Many associations with ageing and age-related 206	  
disease such as Alzheimer’s are complex, often with low effect sizes of individual 207	  
variants, and it is highly likely that at least some of the missing heritability is due to 208	  
environmental interactions [44]. For example, in a mouse model, disease risk in 209	  
predisposed strains was shown to be attenuated by environmental factors when 210	  
Alzheimer-prone mice were placed in a rich and naturalistic environment, showing 211	  
reduced behavioral effects despite increased plaque density [45]. Moreover, the 212	  
induction of a neuroinflammatory response was related to chronic unpredictable 213	  
stress [46]. Conversely, dopamine D4 receptor (DRD4) knockout mice do not show 214	  
the increased longevity seen when background strain mice are brought up in a rich 215	  
environment, showing them to be refractory to the positive effects of a rich 216	  
environment. This study found consistency with a parallel human cohort, presenting 217	  
an excellent paradigm for future work [47]. Individual environmental impact may be 218	  
reflected epigenetically [15]. Such epigenetic individuality is influenced in part by 219	  
biographical parameters, reflecting psychosocial environment, social participation 220	  
and education, and the way this allostatic load was handled by the individual as part 221	  
of her or his stress response. In turn, targeted interventions may be used to 222	  
ameliorate the environment [19]. 223	  
 224	  
Apart from ‘omics’ data processing and analysis, computational studies enable the 225	  
well-founded comparison of human and animal data, as well as simulation studies, 226	  
particularly on the molecular level. At its simplest, the parallelogram approach, 227	  
originally developed in toxicology [48], suggests use of data of diseased animal 228	  
tissue to extrapolate to the often inaccessible human diseased tissue, aided by e.g. 229	  
blood data available for diseased and healthy individuals. Moreover, controlled 230	  
vocabularies and ontologies, describing the formal relationships between concepts 231	  
and entities, are developed to enable the systematic comparison of human and 232	  
animal data [49]. For example, on the (cell) anatomical and physiological level, we 233	  
can then integrate data and analyze the relationship between phenotypes of humans 234	  
and model species, yielding estimates for the extrapolation of data and insights from 235	  
model organisms to humans. Formal data semantics is also useful to systematically 236	  
mine electronic health record data, to describe phenotypes and diseases [50]. 237	  
Furthermore, recent promising developments in systems biology and systems 238	  
medicine include simulation studies of ageing-related pathways and the multi-level 239	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modeling of the large number of interacting processes [51]. Such studies help to 240	  
disentangle the network of interdependent biological processes that underlie ageing, 241	  
and distinguish correlation and causality, following the example of cancer research, 242	  
where computational studies help to distinguish ‘passenger’ and ‘driver’ mutations 243	  
[52]. However, many cancers are characterized by gross modifications of cell and 244	  
organ physiology, e.g. due to chromosomal aberrations. In contrast, ageing 245	  
processes are subtler, triggering weaker patterns and signals in terms of phenotype 246	  
and molecular mechanisms, on a longer time scale. Therefore, the sound integration 247	  
of data using techniques from data semantics and ontologies is important in ageing 248	  
research [53], [54], [55], [56], to maximize our chances of detecting meaningful 249	  
patterns and signals. 250	  
 251	  
 252	  
The implementation of any recommendations for healthspan extension must 253	  
be easy and safe.  254	  
 255	  
Many people show high adherence to moderate modifications of exercise and dietary 256	  
patterns, motivated by their personal instinct or subjective feelings of benefit. Correct 257	  
use and long-term adherence to changes in dietary composition, nutraceuticals and 258	  
food supplements is more difficult, though1. Healthy and health-conscious individuals 259	  
consuming high amounts of fruit and vegetables (> 400 g/day) display a more robust 260	  
organismal antioxidant defense system [57] and a better cognitive performance [58], 261	  
independent of age and gender, compared to subjects consuming < 100 g/day, 262	  
although a good plasma micronutrient status can be achieved through targeted 263	  
counselling [59]. However, as the correct use of nutraceuticals and food supplements 264	  
is complicated [60], most of the supplementation trials with single compounds and/or 265	  
single lifestyle preventive strategies against age-related diseases have largely been 266	  
unsuccessful so far [61]. Furthermore, an immediate subjective feeling of benefit with 267	  
nutraceuticals is not usually attained, while the possible physiological impact may be 268	  
significant (on the positive as well as on the negative side). This also applies to long-269	  
term small-molecule interventions such as calorie-restriction mimetics. Additionally, 270	  
quality and safety of nutraceuticals and food supplements are not as strictly 271	  
controlled as are drugs. Here, subjective feeling has to be supplemented or 272	  
substituted by sound scientific evidence of benefit, subject to a personalized 273	  
approach. The polypill concept [62] is often criticized, exactly because it does not 274	  
consider the specifics on the individual. It consists of intensively tested drugs at low 275	  
dosage, the benefits of which have been shown in large-scale studies. Specifically, it 276	  
aims to reduce the risk of heart attack and stroke, employing one statin and three 277	  
blood pressure reducing agents at around half the standard dose, and in a 278	  
personalized instantiation, it can be considered a model for active interventions to 279	  
stay healthy for longer.  280	  
 281	  
Sound scientific evidence for healthspan effects of interventions in humans is 282	  
becoming available. 283	  
 284	  
Conclusive evidence of therapeutic or prophylactic effects of interventions on human 285	  
healthspan is going to be difficult to establish, because longitudinal intervention 286	  
studies (starting in mid-life) would take around half a century to complete. Moreover, 287	  
interventions designed for presumably healthy people need specific justification, and 288	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  For example, a six-year study on prevention of dementia failed to show positive effects, possibly due 
to increasing non-adherence (Jerant A, Chapman B, Duberstein P, Robbins J, Franks P: Personality 
and medication non-adherence among older adults enrolled in a six-year trial. Br J Health Psychol 
2011;16:151-169. (Figure 2 therein)). 
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no discernible negative side effects. However, a significant delay of ageing-289	  
associated disease and morbidity is a distinct positive effect that should not be 290	  
abandoned without due consideration. Fortunately, there are a couple of convincing 291	  
arguments that indicate the high likelihood of success of finding valid means towards 292	  
healthspan extension [25], with people in their late adulthood as the target group. 293	  
First, very ‘mild’ forms of healthspan-extending interventions have been practiced for 294	  
a long time already; their systematic and personalized improvement is already 295	  
(winning) half the battle. These include exercise, diet and nutraceuticals, as well as 296	  
indication-based interventions such as drug-based blood pressure reduction, 297	  
cholesterol modulation and osteoporosis prevention. Also, for many individuals, a 298	  
significant further extension of healthspan can be expected from improvements in 299	  
their psychosocial environment, social participation and education. While consistent 300	  
good parental care in the early years is a good foundation, psychosocial lifestyle 301	  
interventions can still be effective in adulthood [19]. Second, as a proof of concept, 302	  
dietary restriction has already been demonstrated to extend healthspan in numerous 303	  
animal species including mammals, for example benefitting rhesus monkeys (see 304	  
above), and has been shown to improve biomarkers of ageing in humans in late 305	  
adulthood as well [63]. Moreover, as described above, pharmacological mimetics of 306	  
dietary restriction have shown promising results at least in mouse studies [33]. 307	  
Combination of interventions is important, though, as most of the supplementation 308	  
trials with single compounds and/or single lifestyle preventive strategies were largely 309	  
not successful so far [61]. Third, centenarians frequently feature very late onset of 310	  
age-related diseases and disabilities [64], demonstrating that the goal of healthspan 311	  
extension can indeed be accomplished at very old age.  312	  
 313	  
Conclusions and prospects 314	  
 315	  
We propose a realistic research agenda with distinctive positive advances within one 316	  
decade: 317	  
 318	  
• We need to augment ongoing and future clinical studies, measuring as many 319	  
ageing-related parameters as possible, and to couple them with closely 320	  
similar animal studies, which feature far shorter execution times and more 321	  
possibilities for experimental intervention and detailed study. Here, one main 322	  
aim is to discover and validate new markers of ageing which may assist in 323	  
stratification of populations with regard to the efficacy of therapeutic and 324	  
prophylactic intervention. Critical is the recording of environmental 325	  
parameters, stress, activity and personal history for human studies and 326	  
detailed analysis of the effects of the environment for model organism 327	  
studies. 328	  
 329	  
• We need to systematically validate the evidence gained from model animal 330	  
studies in humans and vice versa. Here, we need an in-depth understanding 331	  
of the molecular processes that are supposed to be the targets of 332	  
intervention. Mechanistic studies in mice are essential, and studies in 333	  
humanized mice, (human) cell lines and other model organisms should be 334	  
undertaken as well, always selecting the most informative approach. 335	  
 336	  
• Finally, given the range of interventions likely to become validated and 337	  
available, we should aim for a combinatorial approach through the 338	  
establishment of a modular system, from which the most appropriate 339	  
combination of interventions (Fig. 1) can be selected by the individual.  340	  
 341	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Such an agenda can be expected to yield validated personalized prescriptions for 342	  
many people within a decade, enabling them to extend their healthspan and to 343	  
shorten the period of their life that is spent in ill health.  344	  
 345	  
Box 1: Economic implications. 346	  
Slowing ageing and extending healthspan has profound economic implications. 347	  
Importantly, maintaining health and fitness for a longer time period enables later 348	  
retirement, and more senior-level contribution to society 349	  
[http://www.healthyageing.eu/]. Furthermore, with the growing lack of young 350	  
employees there is a great need of people working until the age of 70 or older, in 351	  
order to avoid staff shortage, especially in service industries such as medicine. Most 352	  
importantly, however, healthspan increases are one of the few contributors to 353	  
lowering health care costs in a predictable way, by postponing most of the demand 354	  
until very old age [65]. Current repair-oriented approaches in cancer, cardiovascular, 355	  
neuro-degeneration and other areas can then slowly but steadily refocus to serving a 356	  
population of increasingly advanced age, who stay healthy well beyond their 90s. In 357	  
summary, the social, economic, and health benefits that would result from advancing 358	  
healthspan are “longevity dividends” [66]. 359	  
 360	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Fig. 1: Healthspan extension includes activity, diet and other interventions, each of 594	  
which expected to be most effective if personalized, alone and in combination. For 595	  
the "MediterrAsian" diet, see [67]. 596	  
 597	  598	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Fig. 2: Robust research on healthspan extension requires a solid base of systematic 599	  
studies in humans and animals, and an understanding of the biology of ageing, that 600	  
is, of the mechanisms underlying molecular ageing processes. 601	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